vs
HAEMONETICS CORP（HAE）与Reddit, Inc.（RDDT）财务数据对比。点击上方公司名可切换其他公司
Reddit, Inc.的季度营收约是HAEMONETICS CORP的2.0倍（$663.0M vs $339.0M），Reddit, Inc.净利率更高（30.8% vs 13.2%，领先17.6%），Reddit, Inc.同比增速更快（69.0% vs -2.7%），Reddit, Inc.自由现金流更多（$311.0M vs $87.2M），过去两年Reddit, Inc.的营收复合增速更高（53.6% vs 0.4%）
豪洛捷（Haemonetics）是全球血液与血浆供应及服务提供商，于20世纪70年代由艾伦·（杰克）·莱瑟姆博士在马萨诸塞州内蒂克创立，业务围绕血液相关产品及配套服务展开，为全球医疗领域提供血液管理相关的专业解决方案。
Reddit是美国知名的社交新闻聚合与论坛类社交媒体平台，注册用户可发布链接、文字帖、图片、视频等各类内容，其他用户可对内容进行点赞或点踩，内容按主题归类到用户创建的子板块中，获赞更高的内容会排在板块前列，热度足够的内容还将展示在全站首页。
HAE vs RDDT — 直观对比
营收规模更大
RDDT
是对方的2.0倍
$339.0M
营收增速更快
RDDT
高出71.7%
-2.7%
净利率更高
RDDT
高出17.6%
13.2%
自由现金流更多
RDDT
多$223.8M
$87.2M
两年增速更快
RDDT
近两年复合增速
0.4%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $339.0M | $663.0M |
| 净利润 | $44.7M | $204.0M |
| 毛利率 | 59.7% | 100.0% |
| 营业利润率 | 19.9% | 0.0% |
| 净利率 | 13.2% | 30.8% |
| 营收同比 | -2.7% | 69.0% |
| 净利润同比 | 19.3% | 680.0% |
| 每股收益（稀释后） | $0.95 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HAERDDT
| Q1 26 | — | $663.0M | ||
| Q4 25 | $339.0M | $725.6M | ||
| Q3 25 | $327.3M | $584.9M | ||
| Q2 25 | $321.4M | $499.6M | ||
| Q1 25 | $330.6M | $392.4M | ||
| Q4 24 | $348.5M | $427.7M | ||
| Q3 24 | $345.5M | $348.4M | ||
| Q2 24 | $336.2M | $281.2M |
净利润HAERDDT
| Q1 26 | — | $204.0M | ||
| Q4 25 | $44.7M | $251.6M | ||
| Q3 25 | $38.7M | $162.7M | ||
| Q2 25 | $34.0M | $89.3M | ||
| Q1 25 | $58.0M | $26.2M | ||
| Q4 24 | $37.5M | $71.0M | ||
| Q3 24 | $33.8M | $29.9M | ||
| Q2 24 | $38.4M | $-10.1M |
毛利率HAERDDT
| Q1 26 | — | 100.0% | ||
| Q4 25 | 59.7% | 91.9% | ||
| Q3 25 | 59.5% | 91.0% | ||
| Q2 25 | 59.8% | 90.8% | ||
| Q1 25 | 58.4% | 90.5% | ||
| Q4 24 | 55.5% | 92.6% | ||
| Q3 24 | 54.2% | 90.1% | ||
| Q2 24 | 52.0% | 89.5% |
营业利润率HAERDDT
| Q1 26 | — | 0.0% | ||
| Q4 25 | 19.9% | 31.9% | ||
| Q3 25 | 17.9% | 23.7% | ||
| Q2 25 | 16.8% | 13.6% | ||
| Q1 25 | 21.6% | 1.0% | ||
| Q4 24 | 16.9% | 12.4% | ||
| Q3 24 | 15.0% | 2.0% | ||
| Q2 24 | 11.8% | -11.0% |
净利率HAERDDT
| Q1 26 | — | 30.8% | ||
| Q4 25 | 13.2% | 34.7% | ||
| Q3 25 | 11.8% | 27.8% | ||
| Q2 25 | 10.6% | 17.9% | ||
| Q1 25 | 17.5% | 6.7% | ||
| Q4 24 | 10.8% | 16.6% | ||
| Q3 24 | 9.8% | 8.6% | ||
| Q2 24 | 11.4% | -3.6% |
每股收益（稀释后）HAERDDT
| Q1 26 | — | $1.01 | ||
| Q4 25 | $0.95 | $1.24 | ||
| Q3 25 | $0.81 | $0.80 | ||
| Q2 25 | $0.70 | $0.45 | ||
| Q1 25 | $1.17 | $0.13 | ||
| Q4 24 | $0.74 | $4.76 | ||
| Q3 24 | $0.66 | $0.16 | ||
| Q2 24 | $0.74 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $363.4M | $1.4B |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $911.5M | $3.2B |
| 总资产 | $2.5B | $3.5B |
| 负债/权益比越低杠杆越低 | 1.34× | — |
8季度趋势，按日历期对齐
现金及短期投资HAERDDT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $363.4M | $953.6M | ||
| Q3 25 | $296.4M | $911.7M | ||
| Q2 25 | $292.9M | $734.1M | ||
| Q1 25 | $306.8M | $635.7M | ||
| Q4 24 | $320.8M | $562.1M | ||
| Q3 24 | $299.3M | $515.9M | ||
| Q2 24 | $344.4M | $468.0M |
总债务HAERDDT
| Q1 26 | — | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益HAERDDT
| Q1 26 | — | $3.2B | ||
| Q4 25 | $911.5M | $2.9B | ||
| Q3 25 | $849.2M | $2.6B | ||
| Q2 25 | $882.3M | $2.4B | ||
| Q1 25 | $820.8M | $2.2B | ||
| Q4 24 | $906.9M | $2.1B | ||
| Q3 24 | $878.9M | $2.0B | ||
| Q2 24 | $905.4M | $1.9B |
总资产HAERDDT
| Q1 26 | — | $3.5B | ||
| Q4 25 | $2.5B | $3.2B | ||
| Q3 25 | $2.4B | $2.9B | ||
| Q2 25 | $2.5B | $2.6B | ||
| Q1 25 | $2.5B | $2.4B | ||
| Q4 24 | $2.5B | $2.3B | ||
| Q3 24 | $2.5B | $2.2B | ||
| Q2 24 | $2.5B | $2.1B |
负债/权益比HAERDDT
| Q1 26 | — | — | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $93.6M | — |
| 自由现金流经营现金流 - 资本支出 | $87.2M | $311.0M |
| 自由现金流率自由现金流/营收 | 25.7% | 46.9% |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | 2.09× | — |
| 过去12个月自由现金流最近4个季度 | $308.1M | $868.6M |
8季度趋势，按日历期对齐
经营现金流HAERDDT
| Q1 26 | — | — | ||
| Q4 25 | $93.6M | $266.8M | ||
| Q3 25 | $111.3M | $185.2M | ||
| Q2 25 | $17.4M | $111.3M | ||
| Q1 25 | $116.6M | $127.6M | ||
| Q4 24 | $43.8M | $90.0M | ||
| Q3 24 | $48.8M | $71.6M | ||
| Q2 24 | $-27.4M | $28.4M |
自由现金流HAERDDT
| Q1 26 | — | $311.0M | ||
| Q4 25 | $87.2M | $263.6M | ||
| Q3 25 | $106.3M | $183.1M | ||
| Q2 25 | $13.6M | $110.8M | ||
| Q1 25 | $100.9M | $126.6M | ||
| Q4 24 | $35.2M | $89.2M | ||
| Q3 24 | $39.4M | $70.3M | ||
| Q2 24 | $-33.1M | $27.2M |
自由现金流率HAERDDT
| Q1 26 | — | 46.9% | ||
| Q4 25 | 25.7% | 36.3% | ||
| Q3 25 | 32.5% | 31.3% | ||
| Q2 25 | 4.2% | 22.2% | ||
| Q1 25 | 30.5% | 32.3% | ||
| Q4 24 | 10.1% | 20.8% | ||
| Q3 24 | 11.4% | 20.2% | ||
| Q2 24 | -9.8% | 9.7% |
资本支出强度HAERDDT
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 0.4% | ||
| Q3 25 | 1.5% | 0.4% | ||
| Q2 25 | 1.2% | 0.1% | ||
| Q1 25 | 4.7% | 0.2% | ||
| Q4 24 | 2.5% | 0.2% | ||
| Q3 24 | 2.7% | 0.4% | ||
| Q2 24 | 1.7% | 0.4% |
现金转化率HAERDDT
| Q1 26 | — | — | ||
| Q4 25 | 2.09× | 1.06× | ||
| Q3 25 | 2.88× | 1.14× | ||
| Q2 25 | 0.51× | 1.25× | ||
| Q1 25 | 2.01× | 4.88× | ||
| Q4 24 | 1.17× | 1.27× | ||
| Q3 24 | 1.44× | 2.40× | ||
| Q2 24 | -0.71× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
RDDT
暂无分部数据
